Dr. Leah Fung joined Biotheryx as Chief Scientific Officer in 2014 and was pivotal in the design and implementation of the Company’s PRODEGY protein degradation platform. As Chief Scientific Officer, she oversees drug discovery and the strategic expansion of Biotheryx’s pipeline. She created Biotheryx’s Cereblon binder library and directed research that resulted in 25 issued U.S. patents covering an extensive range of small molecules, including Biotheryx’s BTX-1188 molecular glue. Prior, Dr. Fung served as Vice President of Medicinal Chemistry at NovoMedix, where she led drug discovery research efforts to discover antifibrotic and breast cancer development candidates entering into IND-enabling studies. Dr. Fung was also Associate Director of Medicinal Chemistry at Structural Genomix and Assistant Director of Medicinal Chemistry at Structural Bioinformatics. At both companies, she led multi-disciplinary research teams to discover novel cancer therapeutics using fragment-based approaches for lead discovery, as well as crystallography and computational methods for lead optimization. Dr. Fung also held leadership positions at Signal Pharmaceuticals and Celgene. Notably, her research at Celgene led to a selective estrogen receptor modulator co-developed by Novartis and advanced into clinical studies for estrogen receptor-positive breast cancer. Dr. Fung was among leading scientists who pioneered high-throughput parallel synthesis technologies and combinatorial chemistries and has authored or co-authored over 20 peer-reviewed publications. Additionally, she is co-inventor on more than 40 issued U.S. patents and hundreds of international patents. Dr. Fung received her B.S. in chemistry from Azusa Pacific University and a Ph.D. in organic chemistry from the University of California, Irvine.